{"preliminary_commentary":{"by_channel":{"x_thread":9,"youtube":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02064387\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["belantamab mafodotin"]],"indication":"relapsed or refractory multiple myeloma","name":"DREAMM-1","nct_id":"NCT02064387","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dreamm-1-nct02064387. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive GSK2857916 intravenously over 60 minutes (one dose) every 3 weeks (21 day cycle) for a maximum of 16 cycles.","label":"Schedule 1 Part 1","type":"EXPERIMENTAL"},{"description":"Participants may receive GSK2857916 intravenously over 60 minutes (one dose) once weekly for three consecutive weeks followed by 1 week of rest (28 day cycle) for a maximum of 16 cycles.","label":"Schedule 2 Part 1","type":"EXPERIMENTAL"},{"description":"Participants will receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for up to 16 cycles.","label":"Schedule 1 Part 2","type":"EXPERIMENTAL"},{"description":"Participants may receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for a maximum of 16 cycles.","label":"Schedule 2 Part 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2019-08-01","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":79,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"GSK2857916","otherNames":[],"type":"DRUG"}],"last_update":"2020-08-11","lead_sponsor":"GlaxoSmithKline","official_title":"A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects With Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2018-08-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1","timeFrame":"Up to 23.5 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (MM)","timeFrame":"Up to 35 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL)","timeFrame":"Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 1","timeFrame":"Up to Day 21 (from first dose)"},{"measure":"Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1","timeFrame":"Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM)","timeFrame":"Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (NHL)","timeFrame":"Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1","timeFrame":"Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)","timeFrame":"Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)","timeFrame":"Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1","timeFrame":"Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)","timeFrame":"Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)","timeFrame":"Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1","timeFrame":"Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)","timeFrame":"Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)","timeFrame":"Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Grade Change From Baseline in Hematology Data-Part 1","timeFrame":"Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)","timeFrame":"Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)","timeFrame":"Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1","timeFrame":"Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)","timeFrame":"Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)","timeFrame":"Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1","timeFrame":"Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)","timeFrame":"Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)","timeFrame":"Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)"},{"measure":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg","timeFrame":"Baseline and Day 1 (Cycle 2 and 3)"},{"measure":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg","timeFrame":"Baseline and Day 1 (Cycle 2)"},{"measure":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg","timeFrame":"Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13,14, 15)"},{"measure":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg","timeFrame":"Baseline and Day 1 (Cycle 2, 3, 5, 6, 7, 8)"},{"measure":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg","timeFrame":"Baseline and Day 1 (Cycle 2, 3, 4, 5, 6)"},{"measure":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg","timeFrame":"Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 16)"},{"measure":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg","timeFrame":"Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14, 15, 16)"},{"measure":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg","timeFrame":"Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)"},{"measure":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)","timeFrame":"Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)"},{"measure":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL)","timeFrame":"Baseline and Day 1 (Cycle 2)"}],"references":[{"citation":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, He Z, Opalinska JB, Cohen AD. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019 Mar 20;9(4):37. doi: 10.1038/s41408-019-0196-6.","pmid":"30894515","type":"BACKGROUND"},{"citation":"Collins J, van Noort M, Rathi C, Post TM, Struemper H, Jewell RC, Ferron-Brady G. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma. CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1411-1424. doi: 10.1002/psp4.13016. Epub 2023 Aug 2.","pmid":"37465991","type":"DERIVED"},{"citation":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12.","pmid":"30442502","type":"DERIVED"},{"citation":"Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187-99. doi: 10.2217/imt.15.77. Epub 2015 Sep 15.","pmid":"26370838","type":"DERIVED"}],"start_date":{"date":"2014-07-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916","url":"https://clinicaltrials.gov/study/NCT02064387"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dreamm-1-nct02064387"}